In the IQVIA™ LRx database, patients prescribed tafamidis 61 mg in Germany displayed high adherence and persistency rates, which suggest good drug tolerability and ease of use.
Keyphrases
- health insurance
- end stage renal disease
- affordable care act
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- case report
- clinical trial
- adverse drug
- electronic health record
- randomized controlled trial
- healthcare
- big data
- metabolic syndrome
- type diabetes
- machine learning
- data analysis
- patient reported